RU2003115622A - Способ для лечения неврологических и нейропсихологических нарушений - Google Patents
Способ для лечения неврологических и нейропсихологических нарушенийInfo
- Publication number
- RU2003115622A RU2003115622A RU2003115622/14A RU2003115622A RU2003115622A RU 2003115622 A RU2003115622 A RU 2003115622A RU 2003115622/14 A RU2003115622/14 A RU 2003115622/14A RU 2003115622 A RU2003115622 A RU 2003115622A RU 2003115622 A RU2003115622 A RU 2003115622A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- inhibitors
- preceding paragraphs
- medicament
- manufacture
- Prior art date
Links
- 230000000926 neurological effect Effects 0.000 title claims 2
- 230000003557 neuropsychological effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000003001 depressive effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 101710151321 Melanostatin Proteins 0.000 claims 1
- 102400000064 Neuropeptide Y Human genes 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 230000003044 adaptive effect Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 claims 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
Claims (8)
1. Применение ингибитора дипептидилпептидазы IV (DP IV или CD 26) или DP IV-подобного фермента для получения лекарственного средства для модуляции поведенческой и/или неврологической адаптивной реактивности на стресс, в том числе тревожности.
2. Применение по п.1 для получения лекарственного средства для уменьшения деградации эндогенного локализованного в ЦНС нейропептида Y (NPY) и других субстратов, имеющих сходные свойства.
3. Применение по любому из предшествующих пунктов для получения лекарственного средства для лечения психосоматических, депрессивных и психоневрологических заболеваний.
4. Применение по п.3, отличающееся тем, что психосоматические, депрессивные и психоневрологические заболевания выбраны из группы, состоящей из нарушений, связанных с тревожностью, депрессии, бессоницы, хронической усталости, шизофрении, эпилепсии, нарушений питания, спазма и хронической боли.
5. Применение по любому из предшествующих пунктов, отличающееся тем, что ингибиторы используют в комбинации с нейропептидом Y.
6. Применение по любому из предшествующих пунктов, отличающееся тем, что ингибиторы присутствуют в физиологически совместимом носителе для доставки лекарственного средства.
7. Применение по любому из предшествующих пунктов, отличающееся тем, что ингибиторы приготовлены в виде пролекарств этих ингибиторов.
8. Применение по любому из предшествующих пунктов, отличающееся тем, что ингибиторы используют парентерально, энтерально, перорально, ингаляционно или в виде суппозитория.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24403600P | 2000-10-27 | 2000-10-27 | |
| US60/244,036 | 2000-10-27 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006122179/15A Division RU2416406C2 (ru) | 2000-10-27 | 2006-06-20 | Способ для лечения неврологических и нейропсихологических нарушений |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003115622A true RU2003115622A (ru) | 2004-10-27 |
| RU2286149C2 RU2286149C2 (ru) | 2006-10-27 |
Family
ID=22921137
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003115614/14A RU2003115614A (ru) | 2000-10-27 | 2001-10-29 | Способ лечения неврологических и нейропсихологических нарушений |
| RU2003115622/14A RU2286149C2 (ru) | 2000-10-27 | 2001-10-29 | Способ для лечения неврологических и нейропсихологических нарушений |
| RU2006122179/15A RU2416406C2 (ru) | 2000-10-27 | 2006-06-20 | Способ для лечения неврологических и нейропсихологических нарушений |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003115614/14A RU2003115614A (ru) | 2000-10-27 | 2001-10-29 | Способ лечения неврологических и нейропсихологических нарушений |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006122179/15A RU2416406C2 (ru) | 2000-10-27 | 2006-06-20 | Способ для лечения неврологических и нейропсихологических нарушений |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20040043919A1 (ru) |
| EP (2) | EP1328270A2 (ru) |
| JP (2) | JP2004512299A (ru) |
| KR (2) | KR20030096227A (ru) |
| CN (3) | CN1471392A (ru) |
| AT (1) | ATE399008T1 (ru) |
| AU (3) | AU2002221773B2 (ru) |
| BR (2) | BR0114921A (ru) |
| CA (3) | CA2689012A1 (ru) |
| CY (1) | CY1108336T1 (ru) |
| DE (1) | DE60134563D1 (ru) |
| DK (1) | DK1328271T3 (ru) |
| ES (1) | ES2309108T3 (ru) |
| IL (4) | IL155157A0 (ru) |
| NO (2) | NO20031849L (ru) |
| PT (1) | PT1328271E (ru) |
| RU (3) | RU2003115614A (ru) |
| WO (2) | WO2002034242A2 (ru) |
| ZA (2) | ZA200302590B (ru) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1163594C (zh) * | 1997-09-29 | 2004-08-25 | 尖端医疗有限公司 | 体外造血细胞的刺激 |
| US6979697B1 (en) * | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| IL155157A0 (en) * | 2000-10-27 | 2003-10-31 | Probiodrug Ag | Pharmaceutical compositions containing an attractin inhibitor |
| US7132104B1 (en) | 2000-10-27 | 2006-11-07 | Probiodrug Ag | Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders |
| ATE374181T1 (de) | 2001-06-27 | 2007-10-15 | Smithkline Beecham Corp | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
| CN1633420A (zh) | 2002-04-08 | 2005-06-29 | 托伦脱药品有限公司 | 噻唑烷－4－腈和类似物以及它们作为二肽基－肽酶抑制剂的用途 |
| AU2003248921A1 (en) * | 2002-07-09 | 2004-01-23 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
| US20040242566A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| AU2004237408C9 (en) | 2003-05-05 | 2010-04-15 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
| KR20110059664A (ko) | 2003-05-05 | 2011-06-02 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
| EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| CA2535619A1 (en) | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
| CN1867324A (zh) | 2003-10-15 | 2006-11-22 | 前体生物药物股份公司 | 谷氨酰胺酰基环化酶效应物和谷氨酸环化酶效应物的应用 |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| GEP20094679B (en) | 2004-03-15 | 2009-05-10 | Takeda Pharmaceuticals Co | Dipeptidyl peptidase inhibitors |
| US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
| US7872124B2 (en) | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| ME02005B (me) | 2005-09-14 | 2012-08-31 | Takeda Pharmaceuticals Co | Inhibitori dipeptidil peptidaze za lečenje dijabetesa |
| CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| KR20090004950A (ko) | 2006-04-12 | 2009-01-12 | 프로비오드룩 아게 | 효소 억제제 |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| RU2350331C1 (ru) * | 2007-07-10 | 2009-03-27 | Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" | Способ лечения невроза навязчивых состояний |
| RU2350330C1 (ru) * | 2007-11-13 | 2009-03-27 | Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" | Способ лечения истерического невроза |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| JP5734981B2 (ja) | 2009-09-02 | 2015-06-17 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン |
| US8648073B2 (en) | 2009-12-30 | 2014-02-11 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
| US8853212B2 (en) | 2010-02-22 | 2014-10-07 | Merck Sharp & Dohme Corp | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes |
| WO2011146358A1 (en) | 2010-05-21 | 2011-11-24 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| US9073930B2 (en) | 2012-02-17 | 2015-07-07 | Merck Sharp & Dohme | Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| US9668969B1 (en) | 2012-02-22 | 2017-06-06 | Arturo Solis Herrera | Methods of using QIAPINE |
| WO2014018350A1 (en) | 2012-07-23 | 2014-01-30 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-iv inhibitors |
| CN107213465A (zh) * | 2017-06-23 | 2017-09-29 | 武汉大学 | 二肽基肽酶iv抑制剂在制备防治癫痫的药物中的应用 |
| CN119380997B (zh) * | 2024-12-27 | 2025-03-21 | 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) | 一种神经内科康复程度评价方法及系统 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US25023A (en) * | 1859-08-09 | Improved device for making electro-magnetic currents, constant or intermittent | ||
| US2961377A (en) * | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US3879541A (en) * | 1970-03-03 | 1975-04-22 | Bayer Ag | Antihyperglycemic methods and compositions |
| US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
| CH602612A5 (ru) * | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
| US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
| US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
| DE4039415A1 (de) * | 1990-02-03 | 1991-08-08 | Boehringer Mannheim Gmbh | Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest |
| US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
| IL106998A0 (en) * | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
| IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5614379A (en) * | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
| DE122010000020I1 (de) * | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US5827898A (en) * | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| CA2819705C (en) * | 1998-02-02 | 2014-07-08 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| JP2002506075A (ja) * | 1998-03-09 | 2002-02-26 | フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ | セリンペプチダーゼ調節剤 |
| DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| DE19834591A1 (de) * | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
| AU3960400A (en) * | 1999-03-05 | 2000-09-28 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
| US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| US6107317A (en) * | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| ES2525041T3 (es) * | 2000-03-31 | 2014-12-16 | Royalty Pharma Collection Trust | Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención |
| IL155157A0 (en) * | 2000-10-27 | 2003-10-31 | Probiodrug Ag | Pharmaceutical compositions containing an attractin inhibitor |
-
2001
- 2001-10-29 IL IL15515701A patent/IL155157A0/xx unknown
- 2001-10-29 CN CNA01817857XA patent/CN1471392A/zh active Pending
- 2001-10-29 DE DE60134563T patent/DE60134563D1/de not_active Expired - Lifetime
- 2001-10-29 PT PT01988583T patent/PT1328271E/pt unknown
- 2001-10-29 RU RU2003115614/14A patent/RU2003115614A/ru not_active Application Discontinuation
- 2001-10-29 CN CNB018180671A patent/CN1278683C/zh not_active Expired - Fee Related
- 2001-10-29 EP EP01988582A patent/EP1328270A2/en not_active Withdrawn
- 2001-10-29 AU AU2002221773A patent/AU2002221773B2/en not_active Ceased
- 2001-10-29 BR BR0114921-0A patent/BR0114921A/pt not_active Application Discontinuation
- 2001-10-29 CA CA002689012A patent/CA2689012A1/en not_active Abandoned
- 2001-10-29 CA CA2422889A patent/CA2422889C/en not_active Expired - Fee Related
- 2001-10-29 ES ES01988583T patent/ES2309108T3/es not_active Expired - Lifetime
- 2001-10-29 AT AT01988583T patent/ATE399008T1/de active
- 2001-10-29 WO PCT/EP2001/012478 patent/WO2002034242A2/en not_active Ceased
- 2001-10-29 JP JP2002537296A patent/JP2004512299A/ja not_active Withdrawn
- 2001-10-29 WO PCT/EP2001/012479 patent/WO2002034243A2/en not_active Ceased
- 2001-10-29 KR KR10-2003-7005769A patent/KR20030096227A/ko not_active Ceased
- 2001-10-29 IL IL15511601A patent/IL155116A0/xx unknown
- 2001-10-29 ZA ZA200302590A patent/ZA200302590B/en unknown
- 2001-10-29 BR BR0114924-5A patent/BR0114924A/pt not_active IP Right Cessation
- 2001-10-29 CA CA002424475A patent/CA2424475A1/en not_active Abandoned
- 2001-10-29 RU RU2003115622/14A patent/RU2286149C2/ru not_active IP Right Cessation
- 2001-10-29 EP EP01988583A patent/EP1328271B1/en not_active Expired - Lifetime
- 2001-10-29 DK DK01988583T patent/DK1328271T3/da active
- 2001-10-29 US US10/415,263 patent/US20040043919A1/en not_active Abandoned
- 2001-10-29 KR KR10-2003-7005718A patent/KR20040025875A/ko not_active Withdrawn
- 2001-10-29 CN CNA2006101219115A patent/CN101143217A/zh active Pending
- 2001-10-29 AU AU2002227898A patent/AU2002227898A1/en not_active Abandoned
- 2001-10-29 AU AU2177302A patent/AU2177302A/xx active Pending
- 2001-10-29 ZA ZA200302394A patent/ZA200302394B/en unknown
- 2001-10-29 JP JP2002537297A patent/JP2004512300A/ja active Pending
-
2003
- 2003-03-27 IL IL155116A patent/IL155116A/en not_active IP Right Cessation
- 2003-04-24 NO NO20031849A patent/NO20031849L/no unknown
- 2003-04-25 NO NO20031867A patent/NO20031867L/no not_active Application Discontinuation
-
2006
- 2006-06-20 RU RU2006122179/15A patent/RU2416406C2/ru not_active IP Right Cessation
-
2008
- 2008-09-11 CY CY20081100982T patent/CY1108336T1/el unknown
-
2009
- 2009-02-11 IL IL196994A patent/IL196994A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003115622A (ru) | Способ для лечения неврологических и нейропсихологических нарушений | |
| RU2006122179A (ru) | Способ для лечения неврологических и нейропсихологических нарушений | |
| DE69834658D1 (de) | Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität | |
| ATE450269T1 (de) | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten | |
| IL267381A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
| DE60227658D1 (de) | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren | |
| WO2007029249A3 (en) | Oligoribonucleotides and methods of use thereof for treatment of cardiovascular diseases | |
| IL157821A0 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv | |
| MXPA04005790A (es) | Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona. | |
| WO2001045641A3 (en) | Inhibitors of thrombin induced platelet aggregation | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| WO2005058233A3 (en) | Methods for treatment of acute pancreatitis | |
| ATE309795T1 (de) | Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes | |
| NZ544719A (en) | Combination of mGluR2 antagonist and aChE inhibitor for treatment of acute and/or chronic neurological disorders | |
| ATE465743T1 (de) | Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen | |
| WO2001041754A8 (en) | Inhibitors of collagen-induced platelet aggregation | |
| GB0130677D0 (en) | Medicaments and novel compounds | |
| TW200509929A (en) | Treatment of bipolar disorders and associated symptoms | |
| DE602005026276D1 (de) | Myricitrin verbindungen zur behandlung von schlafstörungen | |
| ATE491715T1 (de) | Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten | |
| WO2004062684A3 (en) | Treatment of thrombocytopenia with inhibitors of pacap | |
| WO2002062327A3 (en) | Method of treating neurological disorders using acetone derivatives | |
| ATE310509T1 (de) | Methode zur behandlung eines analgesiebedürftigen patienten | |
| Gustafson et al. | Clinical experience with levetiracetam treating refractory, symptomatic seizures in children | |
| ATE359995T1 (de) | Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit |